Barcelona Clinic Liver Cancer

Barcelona Clinic Liver Cancer
Name	Barcelona Clinic Liver Cancer
Specialty	Hepatology, Oncology, Surgery
Developed by	Hospital Clínic de Barcelona, Josep Llovet, Ramon Bataller
First published	1999

Barcelona Clinic Liver Cancer

The Barcelona Clinic Liver Cancer (BCLC) staging and treatment allocation system is a widely used clinical model for stratifying patients with hepatocellular carcinoma and guiding therapeutic decisions across multidisciplinary teams at centers such as Hospital Clínic de Barcelona, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Royal Free Hospital, and National Cancer Institute. It integrates tumor burden, liver function measures exemplified by Child–Pugh score and performance status elements drawn from Eastern Cooperative Oncology Group (ECOG) criteria to recommend stage-specific interventions ranging from resection and transplantation to locoregional therapies and systemic agents like sorafenib and atezolizumab.

Overview

The BCLC framework combines variables from tumor staging systems such as TNM staging and concepts from prognostic indices like the Okuda staging system and CLIP score to produce an actionable algorithm used in clinical practice, guidelines from bodies including European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD), and recommendations cited by agencies such as NICE and WHO. Originating at Hospital Clínic de Barcelona under investigators including Josep M. Llovet and collaborators from centers such as Institut Gustave Roussy and King's College Hospital, the BCLC links tumor stage with therapy options and expected survival estimates and has influenced trial designs at institutions like MD Anderson Cancer Center and Dana-Farber Cancer Institute.

History and Development

BCLC emerged in the late 1990s amid competing schemes like Okuda staging and TNM classification (AJCC), with seminal publications authored by Josep Llovet and colleagues who synthesized evidence from surgical series at Hospital Clínic de Barcelona and population studies from registries such as Surveillance, Epidemiology, and End Results Program and European Cancer Registry. Iterative updates in 2000, 2004, 2008, 2012, and 2022 incorporated shifts driven by landmark trials including the SHARP trial for sorafenib, the IMbrave150 trial for atezolizumab plus bevacizumab, and randomized data from locoregional interventions evaluated at centers like Cleveland Clinic and Hôpital Beaujon. Influential investigators and institutions—including Ramon Bataller, Andrew L. Warshaw, Liver Cancer Institute (Zhongshan Hospital)—contributed validation cohorts and methodological critiques.

Staging System

The BCLC classifies patients into stages 0 (very early), A (early), B (intermediate), C (advanced), and D (terminal), aligning with surgical volumes at referral centers such as Hospital Clínic de Barcelona, transplantation activity at programs like University of California, San Francisco and Hospital Universitari Vall d'Hebron, and systemic oncology protocols from groups including EORTC and SWOG. It utilizes tumor size and number parameters comparable to Milan criteria and University of California, San Francisco (UCSF) criteria for transplantation candidacy, couples these with Child–Pugh categories, and integrates performance status metrics from ECOG to inform allocations to resection, ablation, transarterial chemoembolization (TACE), radioembolization (Yttrium-90), systemic therapy, or best supportive care commonly coordinated with palliative services at institutions like St Christopher's Hospice.

Treatment Recommendations

For BCLC 0–A the algorithm favors curative options mirrored in practice at Massachusetts General Hospital and Toronto General Hospital: surgical resection, percutaneous radiofrequency ablation (RFA), and liver transplantation per Milan criteria or expanded criteria like UCSF criteria. For BCLC B, it recommends TACE—a standard at interventional radiology centers including Mount Sinai Hospital and Royal Prince Alfred Hospital—while acknowledging alternate locoregional modalities such as transarterial radioembolization used in trials at Paul Scherrer Institute. For BCLC C, systemic therapy with agents validated in trials conducted by groups like SHARP trial investigators and sponsors such as Bayer and Genentech is advised, now including checkpoint inhibitor regimens supported by IMbrave150 data. For BCLC D, the model directs palliative and supportive measures coordinated with oncology and palliative networks like European Society for Medical Oncology (ESMO).

Prognostic Validation and Outcomes

Numerous external validation studies from centers such as Seoul National University Hospital, Beijing Cancer Hospital, Hospital Clínic de Barcelona, Hôpital Beaujon, and population cohorts from SEER Program and UK National Cancer Registration and Analysis Service have examined BCLC's prognostic discrimination and calibration. Meta-analyses conducted by research groups at University of Barcelona, University of Birmingham, and Kyushu University have compared survival outcomes across BCLC strata and alternative systems like CLIP score and JIS score, demonstrating consistent stage-specific survival gradients but variable predictive accuracy across etiologies such as hepatitis B and hepatitis C and across liver dysfunction spectrums exemplified by alcoholic liver disease and nonalcoholic fatty liver disease.

Implementation and Clinical Impact

BCLC has informed national and international guidelines from EASL, AASLD, NCCN, and Japanese Society of Hepatology and shaped referral patterns at tertiary centers including Hospital Clínic de Barcelona, Cleveland Clinic, and Charité – Universitätsmedizin Berlin. It has influenced trial eligibility criteria used by cooperative groups like EORTC, SWOG, and JCOG and payer policies in jurisdictions overseen by agencies such as NICE and CMS. Educational programs at universities like University of Barcelona School of Medicine, Harvard Medical School, and University of Oxford incorporate BCLC in curricula for hepatology, surgical oncology, and interventional radiology.

Criticisms and Limitations

Critiques from investigators at University of Tokyo, Mayo Clinic, and Royal Free Hospital highlight that the BCLC may be overly prescriptive, potentially excluding patients who benefit from individualized approaches such as extended resection beyond criteria used in trials from UCSF or combined modality strategies evaluated at MD Anderson Cancer Center. Concerns include limited granularity for intermediate BCLC B heterogeneity noted by groups at Barcelona Clinic collaborators and disparities in applicability across regions with differing donor availability at transplant centers like King's College Hospital or variable access to systemic agents in low-resource settings overseen by WHO. Ongoing proposals from consortia including ILCA and researchers at Hospital Clínic de Barcelona aim to refine stage subclassifications and integrate biomarkers such as AFP and molecular signatures identified by initiatives at The Cancer Genome Atlas.

Category:Hepatology